Ceres Nanosciences, Inc.

Ceres Nanosciences Inc. ("Ceres") is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology. The Nanotrap® was invented by a team of George Mason University professors to better capture low-abundance protein biomarkers and protect them from degradation. The Nanotrap® collection process, coupled with existing clinical diagnostic platforms, improves the sensitivity and accuracy of a wide array of critical diagnostic processes. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs. Ceres currently sells R&D kits containing the Nanotrap® technology for use in a broad range of research applications. Ceres' product pipeline includes advanced sample collection technologies and diagnostic tests. Ceres' lead diagnostic test in development is a direct antigen test for the diagnosis of Lyme disease. Ceres is also developing advanced sample preservation tools for the US Department of Defense.